Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. | Oncoimmunology;2(8): e25123, 2013 Aug 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.

Rosa, Roberta; Damiano, Vincenzo; Formisano, Luigi; Nappi, Lucia; Marciano, Roberta; Veneziani, Bianca Maria; De Placido, Sabino; Bianco, Roberto.

Affiliation

Rosa R; Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli "Federico II"; Naples, Italy.

Oncoimmunology ; 2(8): e25123, 2013 Aug 01.

Article in En | MEDLINE | ID: mdl-24083076

Key words

TLR9; everolimus; mTOR; microenvironment; renal cell carcinoma

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncoimmunology Year: 2013 Document type: Article Affiliation country: Italy Country of publication: United States

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncoimmunology Year: 2013 Document type: Article Affiliation country: Italy Country of publication: United States